Jack Higgins Sells 13,200 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 13,200 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $25.32, for a total transaction of $334,224.00. Following the sale, the insider owned 65,050 shares in the company, valued at $1,647,066. This represents a 16.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Down 2.4%

IMNM traded down $0.60 on Tuesday, hitting $23.95. The company had a trading volume of 1,165,720 shares, compared to its average volume of 1,334,804. The business’s fifty day simple moving average is $25.34 and its 200 day simple moving average is $22.73. Immunome, Inc. has a 12-month low of $8.93 and a 12-month high of $30.06. The company has a market cap of $2.72 billion, a PE ratio of -9.47 and a beta of 2.13.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, August 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.14). On average, analysts anticipate that Immunome, Inc. will post -2.38 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Citigroup restated a “buy” rating on shares of Immunome in a report on Thursday, July 9th. Barclays began coverage on shares of Immunome in a research note on Thursday, May 28th. They issued an “overweight” rating and a $36.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $40.00 target price on shares of Immunome in a research report on Thursday, September 10th. Truist Financial upped their target price on Immunome from $37.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, August 12th. Finally, Wall Street Zen downgraded Immunome from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. Twelve equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Immunome presently has an average rating of “Moderate Buy” and an average target price of $34.64.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. bought a new position in Immunome in the 2nd quarter worth about $186,588,000. Wellington Management Group LLP boosted its holdings in shares of Immunome by 10.1% in the second quarter. Wellington Management Group LLP now owns 5,210,216 shares of the company’s stock valued at $110,404,000 after purchasing an additional 478,239 shares during the period. Primecap Management Co. CA bought a new position in Immunome in the second quarter worth approximately $97,081,000. Sofinnova Investments Inc. increased its holdings in Immunome by 271.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,618,477 shares of the company’s stock worth $34,765,000 after purchasing an additional 1,182,426 shares during the period. Finally, Readystate Asset Management LP increased its holdings in Immunome by 23.3% during the 2nd quarter. Readystate Asset Management LP now owns 1,605,820 shares of the company’s stock worth $34,027,000 after purchasing an additional 303,958 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing antibody-based therapies for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies designed to identify therapeutic candidates from human immune responses and advance them into clinical development.

Immunome’s activities include the development of novel immunotherapies and targeted biologic medicines, with research programs aimed at addressing significant unmet needs in oncology and inflammatory or immune-mediated diseases.